Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Hoffmann-La Roche
Kura Oncology, Inc.
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Incyte Corporation
Bristol-Myers Squibb
Sanofi
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.